Vaxart Inc Stock Price, News & Analysis

Vaxart (OTCQX: VXRT), a clinical-stage biotech company developing oral recombinant pill vaccines, will host a virtual stockholder fireside chat on August 20, 2025, at 4:30 p.m. ET to discuss its reverse stock split proposal. Leading proxy advisory firms ISS and Glass Lewis have recommended stockholders support the proposal, which aims to regain Nasdaq compliance.

The company's management team will address stockholder questions during the event, with investors able to submit questions in advance. Stockholders of record as of July 29, 2025, can vote on the proposal until September 4, 2025.

[]

Vaxart (OTCQX: VXRT) reported Q2 2025 financial results and provided significant updates across its vaccine pipeline. The company reported revenue of $39.7M (vs $6.4M in Q2 2024) and a net loss of $15.0M. Key developments include positive topline data from their second-generation norovirus vaccine trial, showing statistically significant increases in blocking antibodies (141% for GI.1 and 94% for GII.4) compared to first-generation constructs.

The company's COVID-19 Phase 2b trial enrolled approximately 5,000 participants before receiving a stop work order, with follow-up continuing for all dosed participants. Vaxart ended Q2 with $26.3M in cash and equivalents, projecting runway into 2026. The company will hold a special stockholder meeting on September 5, 2025, to vote on a potential reverse stock split to regain Nasdaq compliance.

Vaxart (OTCQX: VXRT) CEO Steven Lo has issued a critical letter to stockholders urging them to vote in favor of a reverse stock split proposal by September 4, 2025. The proposal aims to facilitate relisting on Nasdaq after the company's recent delisting. The letter outlines key benefits of a Nasdaq listing, including broader investor access, enhanced visibility, and improved financial flexibility.

The company provided updates on its clinical programs: The COVID-19 Phase 2b trial has enrolled approximately 5,000 participants before receiving a stop work order, with topline data expected in late 2026. Their Norovirus vaccine showed positive Phase 1 results, and their Avian Influenza candidate demonstrated 100% protection in preclinical studies. Vaxart has extended its cash runway into 2026.

Vaxart (OTCQX:VXRT) has scheduled its Q2 2025 business update and financial results conference call for August 13, 2025, at 4:30 p.m. ET, following the market close. The company will provide a comprehensive business update and report financial results for the quarter ended June 30, 2025.

Investors can access the conference call through a webcast or by dialing (877) 407-0832 for domestic calls or (201) 689-8433 for international calls using Conference ID 13755103. Written questions can be submitted in advance to ir@vaxart.com by August 12, 2025. A replay will be available on Vaxart's website after the event.

Vaxart (OTCQX: VXRT), a clinical-stage biotech company developing oral recombinant pill vaccines, has filed a preliminary proxy statement proposing a reverse stock split to regain Nasdaq compliance. The company will hold a Special Meeting of Stockholders on September 5, 2025, to vote on a reverse split ratio between 1-for-5 and 1-for-20.

Following trading suspension due to non-compliance with Nasdaq's minimum bid price requirements, Vaxart has appealed and scheduled a Nasdaq Hearings Panel meeting for August 14, 2025. The new proposal includes reducing authorized shares proportionally to the split ratio, incorporating feedback from stockholders after a previous failed vote in June 2025.

Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company developing oral recombinant pill vaccines, announced its transition to trading on the OTCQX Best Market effective July 8, 2025. The company received a delisting notice from Nasdaq and has requested a hearing before the Nasdaq Hearings Panel, with its stock currently suspended from Nasdaq trading.

CEO Steven Lo emphasized the company's commitment to advancing their proprietary oral pill vaccine development while considering all options regarding their stock listing. Shareholders are not required to take any action regarding this trading transition.

Vaxart (VXRT) held its Annual Meeting of Stockholders with mixed voting results. Shareholders approved two key proposals: the election of six directors to serve until 2026 and the ratification of WithumSmith+Brown as the company's independent auditor. However, stockholders rejected two significant proposals: a reverse stock split amendment and the "say-on-pay" advisory vote on executive compensation. The company is currently evaluating its options regarding the rejected reverse split proposal. The final voting results will be reported in an upcoming Form 8-K filing with the SEC.

Vaxart (VXRT) announced positive Phase 1 clinical trial results for its second-generation oral norovirus vaccine, showing significantly stronger antibody responses compared to its first-generation technology. The trial involved 60 healthy volunteers and demonstrated a 141% increase in GI.1 and 94% increase in GII.4 norovirus blocking antibodies. The vaccine candidates were safe and well-tolerated across all dose groups. This advancement is significant as there is currently no approved vaccine for norovirus, which causes approximately 685 million infections globally annually and creates an economic burden of $60 billion worldwide. Pending partnership or funding, Vaxart plans to initiate a Phase 2b study in late 2025, followed by potential Phase 3 trials in 2026. The company's proprietary oral pill technology, enhanced in 2023-2024, aims to improve antigen protein expression and manufacturability.

Vaxart (NASDAQ: VXRT), a clinical-stage biotech company developing oral recombinant pill vaccines, announced it will host a conference call on June 11, 2025, at 8:30 AM ET to discuss topline results from its Phase I norovirus trial. The company will release the data before market open. Management will review the data and provide a trial update during the call. Investors can access the webcast through provided links and submit questions in advance to ir@vaxart.com. A replay will be available on Vaxart's website after the event.